Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Gemcabene in Adults With FPLD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03508687
Recruitment Status : Recruiting
First Posted : April 26, 2018
Last Update Posted : April 26, 2018
Sponsor:
Information provided by (Responsible Party):
Elif Oral, University of Michigan

Brief Summary:
The overall objective of this study is to assess the efficacy and safety of two dosing regimens of gemcabene (300 mg once daily for 24 weeks or 300 mg daily for 12 weeks followed by 600 mg daily for 12 weeks) in up to eight patients with Familial Partial Lipodystrophy with high triglycerides and Non-Alcoholic Fatty Liver Disease. The study will consist of a six week Wash Out Period, up to a 28 day Screening Period, a 24 week Treatment Period, and a follow-on safety assessment four weeks post final dose. Study participation will last approximately 4 months and includes at least 9 study visits, and can be as many as 11 study visits.

Condition or disease Intervention/treatment Phase
Familial Partial Lipodystrophy Hypertriglyceridemia Fatty Liver NASH - Nonalcoholic Steatohepatitis Drug: 300mg Gemcabene Drug: 600mg Gemcabene Phase 1 Phase 2

Detailed Description:
Patients with typical Familial Partial Lipodystrophy Disease (FPLD) have a marked loss of subcutaneous fat from the extremities and trunk accompanied by a variable amount of excess fat deposition in the nonlipodystrophic areas such as the face, chin, back, and intraabdominal regions. Dietary fat restriction and other lifestyle changes are first line therapy to avoid weight gain, critical for effective management of metabolic complications in patients with lipodystrophy. However, despite lifestyle changes and conventional hypoglycemic and hypolipidemic therapies, some FPLD patients continue to have extreme hypertriglyceridemia, hepatic steatosis, and poorly controlled diabetes.Hypertriglyceridemia is a common condition of FPLD and serum triglyceride levels of 250-1999 mg/dL, classified as moderate to severe hypertriglyceridemia, indicate risk for development of very severe hypertriglyceridemia, causative of pancreatitis and hepatic steatosis. In patients such as those with FPLD with severe or very severe hypertriglyceridemia, fibrates, omega-3 fatty acids (OMG-3) and occasionally niacin are first-line therapy. Non-alcoholic fatty liver disease (NAFLD) is often associated with FPLD. The spectrum of NAFLD associated with FPLD which appears to be more frequent than what is seen in common Type 2 diabetes and appears more severe than common forms of NAFLD and very often associated with NASH. The etiology for the latter is not clear, however, the fact that a mouse model of liver specific laminopathy develops NASH in a cell -autonomous manner suggests that the specific cellular defects seen in FPLD may play a role in the development of NAFLD/NASH. Triglyceride content in the liver is regulated by fatty acid uptake as well as fatty acid and VLDL production rates. Derangements in these processes, such as excessive production of fatty acids and triglycerides that can occur with excessive carbohydrate consumption contribute to NAFLD. Patients with NAFLD compared to controls, present with an atherogenic dyslipidemic profile, characterized by increased serum levels of triglycerides, ApoB, VLDL-C, and LDL-C with a proportionally greater content of small dense LDL-C (sdLDL-C) 18-20. NAFLD is also associated with aberrant nuclear receptor function and systemic inflammation. NAFLD can progress to NASH. NASH is marked by hepatocyte ballooning and liver inflammation, which may progress to scarring and irreversible damage. Macro and microscopically, NASH is characterized by lobular and/or portal inflammation, varying degrees of fibrosis, hepatocyte death and pathological angiogenesis. At its most severe, NASH can progress to cirrhosis, hepatocellular carcinoma (HCC) and liver failure. It is estimated that 20-33% NAFLD patients will progress to NASH, with about 5% ultimately progressing to cirrhosis. Cirrhosis has a reported 7- to 10-year mortality of 12-25%. As NAFLD and NASH continue to be a growing epidemic, gemcabene's clinical and preclinical data suggest that this novel agent may provide benefit to patients with the diagnosis of NAFLD and/or NASH. As such, further development of gemcabene may help meet an unmet medical need in these patient populations. In Phase 2 studies, gemcabene has shown triglyceride lowering from 20 to > 50% based on dose and severity of hypertriglyceridemia and lowering in hsCRP of up to 50%. Additionally, in animal and cell based models, gemcabene studies have provided evidence demonstrating: reduction in de-novo lipogenesis, reduction in intrahepatic TG levels, modulation of inflammation and reduction of the NAFLD activity score, particularly related to hepatic ballooning, steatosis, fibrosis, and collagen accumulation. As such gemcabene may have utility in hypertriglyceridemia of FLP and ultimately in the prevention or treatment of NASH in these patients.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 8 participants
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Investigator-Initiated Open-Label, Randomized Study of Gemcabene in Adults With Familial Partial Lipodystrophy Disease (FPLD)
Actual Study Start Date : March 13, 2018
Estimated Primary Completion Date : March 1, 2020
Estimated Study Completion Date : March 1, 2020


Arm Intervention/treatment
Experimental: 300mg Gemcabene daily week 1-12
Patients will receive 300mg gemcabene daily for weeks 1-12, starting on Day 1/ Visit T1.
Drug: 300mg Gemcabene
300mg Gemcabene

Experimental: Group 1: 300 mg Gemcabene daily week 12-24
After 12 weeks, at visit T4, patients will be randomized 1:1 according to pre-generated randomization code to either of the following groups. Group 1: Gemcabene 300mg daily for weeks 12-24. Group 2: Gemcabene 600mg daily for weeks 12-24. This arm will receive 300mg Gemcabene daily for 12 weeks total, starting at week 12.
Drug: 300mg Gemcabene
300mg Gemcabene

Experimental: Group 2: 600mg Gemcabene daily week 12-24
After 12 weeks, at visit T4, patients will be randomized 1:1 according to pre-generated randomization code to either of the following groups. Group 1: Gemcabene 300mg daily for weeks 12-24. Group 2: Gemcabene 600mg daily for weeks 12-24. This arm will receive 600mg Gemcabene daily for 12 weeks total, starting at week 12.
Drug: 600mg Gemcabene
600mg Gemcabene




Primary Outcome Measures :
  1. Change in fasting serum triglyceride (at 12 weeks) [ Time Frame: Baseline to week 12 ]
    This is measured by percent change in fasting serum triglyceride from baseline to week 12


Secondary Outcome Measures :
  1. Change in fasting serum triglycerides (through 24 weeks) [ Time Frame: Baseline, week 6 and week 12, week 24 ]
    This is measured by change in fasting serum triglyceride from baseline to average of weeks 6 and 12, and week 24 and change in fasting serum triglyceride from baseline to week 12

  2. Percent change in fasting serum triglycerides (through 24 weeks) [ Time Frame: Baseline, week 6 and week 12, week 24 ]
    This is measured by percent change in fasting serum triglyceride from baseline to average of weeks 6 and 12, and week 24 and change in fasting serum triglyceride from baseline to week 12

  3. Change in liver fat content as measured by MRI-PDFF [ Time Frame: Baseline, week 12, week 24 ]
    This is measured by change in liver fat content using MRI-PDFF from baseline to week 12 and week 24

  4. Percent change in liver fat content as measured by MRI-PDFF [ Time Frame: Baseline, week 12, week 24 ]
    This is measured by percent change in liver fat content using MRI-PDFF from baseline to week 12 and week 24

  5. Change in liver fibrosis [ Time Frame: Baseline, Week 12, and Week 24 ]
    This is measured by change in liver fibrosis using MR-elastography from baseline to week 12 and week 24

  6. Percent change in liver fibrosis [ Time Frame: Baseline, Week 12, and Week 24 ]
    This is measured by percent change in liver fibrosis using MR-elastography from baseline to week 12 and week 24

  7. Change in NAS (non-alcoholic steatohepatitis) [ Time Frame: Baseline to week 24 ]
    This is measured by change in NAS via non-alcoholic fatty liver disease activity score including steatosis, lobular inflammation and hepatocyte ballooning from baseline to week 24

  8. Percent change in NAS (non-alcoholic steatohepatitis) [ Time Frame: Baseline to week 24 ]
    This is measured by percent change in NAS via non-alcoholic fatty liver disease activity score including steatosis, lobular inflammation and hepatocyte ballooning from baseline to week 24

  9. Change in biomarkers of inflammation [ Time Frame: Baseline, week 12, week 24 ]
    This is measured by change in interleukin-6 (IL-6), interleukin 1β (IL-1β), angiopoietin like 4 transpeptidase (ANGPTL4), angiopoietin like 3 transpeptidase (ANGPTL3), high-sensitivity C-reactive protein (hsCRP), fibrinogen, serum amyloid A (SAA), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) from baseline to weeks 12 and week 24

  10. Percent change in biomarkers of inflammation [ Time Frame: Baseline, week 12, week 24 ]
    This is measured by percent change in interleukin-6 (IL-6), interleukin 1β (IL-1β), angiopoietin like 4 transpeptidase (ANGPTL4), angiopoietin like 3 transpeptidase (ANGPTL3), high-sensitivity C-reactive protein (hsCRP), fibrinogen, serum amyloid A (SAA), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) from baseline to weeks 12 and week 24

  11. Change in cholesterol [ Time Frame: Baseline, week 6 and week 12, week 24 ]
    This will be measured by change in total, HDL and LDL levels in mg/dL

  12. Percent change in cholesterol [ Time Frame: Baseline, week 6 and week 12, week 24 ]
    This will be measured as percent change in total, HDL and LDL levels in mg/dL

  13. Change in apolipoprotein [ Time Frame: Baseline, week 6 and week 12, week 24 ]
    This will be measured by change in apolipoprotein A and B in mg/dL

  14. Percent change in apolipoprotein [ Time Frame: Baseline, week 6 and week 12, week 24 ]
    This will be measured by percent change in apolipoprotein A and B in mg/dL



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
  • Clinical diagnosis of lipodystrophy based on a lack of body fat in a partial fashion assessed by physical examination, and at least 1 MAJOR criterion (below):
  • Low skinfold thickness in anterior thigh by caliper measurement: men (≤ 10 mm) and women (≤ 22 mm) OR
  • Historic genetic diagnosis of familial partial lipodystrophy (e.g. mutations in LMNA, PPAR-γ, AKT2, or PLIN1 genes) as supported by source documentation
  • Hepatic steatosis (>10% - Stage 2 or 3) as demonstrated by MRI-PDFF;
  • Alcohol intake of less than 20 g per day in females and 30 g per day in males (one 12 oz beer, one glass of wine, or 2 oz of spirits or liquor equals roughly 10 g of alcohol;
  • Mean fasting triglyceride value ≥ 250 mg/dL at the Screening Visit;
  • Background lipid lowering medications must be stable for at least 6 weeks prior to the Screening Visit;
  • Women patients must not be pregnant or lactating and women of child-bearing potential must agree to use acceptable methods of contraception throughout the duration of the study and for 30 days after the last dose of study drug. Male patients must agree to use contraception by means of a condom and may not donate sperm throughout the duration of the study and for 8 days after the last dose of study drug.
  • Weight greater than 50 kg (~110 lbs); with a body mass index (BMI) of no more than 45 kg/m²;
  • Have not used a fibrate with in the last 6 weeks and/or thiazolidinediones (TZDs) within the last 12 weeks prior to the Screening visit.
  • Do not have a hypersensitivity or a history of significant reactions of fibrates.
  • Are not currently taking potent CYP3A4 inhibitors such as itraconazole or a macrolide antibiotic.
  • Have a condition or finding which, in the opinion of the Investigator, would compromise the patient's safety or participation in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03508687


Contacts
Layout table for location contacts
Contact: Elif A Oral, M.D. 734-615-7271 eliforal@med.umich.edu
Contact: Adam H Neidert, M.A. 734-615-0539 aneidert@med.umich.edu

Locations
Layout table for location information
United States, Michigan
University of Michigan Recruiting
Ann Arbor, Michigan, United States, 48105
Contact: Adam H Neidert, MS    734-615-0539    aneidert@med.umich.edu   
Contact: Elif A Oral, MD    734-615-7271    eliforal@med.umich.edu   
Principal Investigator: Elif A Oral, MD         
Sub-Investigator: Nevin N Ajluni, MD         
Sub-Investigator: Corey Lager, MD         
Sponsors and Collaborators
Elif Oral
Investigators
Layout table for investigator information
Principal Investigator: Elif A Oral, M.D. University of Michigan

Layout table for additonal information
Responsible Party: Elif Oral, Associate Professor of Medicine, University of Michigan
ClinicalTrials.gov Identifier: NCT03508687     History of Changes
Other Study ID Numbers: HUM00130803
First Posted: April 26, 2018    Key Record Dates
Last Update Posted: April 26, 2018
Last Verified: April 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Fatty Liver
Non-alcoholic Fatty Liver Disease
Hypertriglyceridemia
Lipodystrophy
Lipodystrophy, Familial Partial
Liver Diseases
Digestive System Diseases
Hyperlipidemias
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases
Skin Diseases, Metabolic
Skin Diseases